Jul 5, 2025, 21:40

Melanoma Research Alliance 2024–2025 Research Awards

The Melanoma Research Alliance (MRA) invites proposals for pre-clinical, translational, and early clinical melanoma research—supporting high-impact projects in prevention, detection, diagnosis, and treatment through multiple award mechanisms totaling at least $9.2 million.

Eligibility Criteria:

Investigators Worldwide: Applications from all countries and diverse backgrounds encouraged.
Award Types & Career Stages:
- Established Investigator Awards (senior faculty with track record)
- Young Investigator Awards (early-career researchers)
- Pilot Awards (exploratory studies)
- Dermatology Career Development Awards (clinician-scientists)
- Special Opportunity Team Science Awards (multi-disciplinary collaborations)
- Academic-Industry Partnership Awards (for Established Investigators and Team Science Awards)
Special Focus Streams:
- Acral Melanoma (Established, Young, Pilot)
- Uveal Melanoma (Established, Young, Uveal Pilot co-funded with A Cure in Sight)
- Pediatric Melanoma Team Science (co-funded with St. Baldrick’s Foundation)
- Neoadjuvant Treatment Translational Team Science
- Radiation Oncology Young Investigator (co-funded with ASTRO)
- Young Investigator proposals from Australia, Israel, or the UK

Funding Details:

Total Commitment: At least $9.2 million across all awards.
Award Sizes: Vary by mechanism—from Pilot Awards (~$50–100 K) to Established Investigator Awards (up to $500 K–1 M), per detailed RFP terms and conditions.
Duration: Generally 1–3 years, depending on award type.
Use of Funds: Direct research costs (personnel, consumables, assays, data analysis, small equipment), travel to scientific meetings, and for Academic-Industry Partnerships, costs related to collaboration and technology transfer. No institutional overhead beyond caps in RFP.

Where to Apply & Further Information:

Submit all materials via proposalCENTRAL.

Access the full RFP, Award Terms & Conditions, and application templates on the MRA website.

Questions?

Contact Joan Levy, PhD, Chief Science Officer.

acral melanoma career development established-investigator Melanoma MRA Neoadjuvant OncoDaily Oncology pediatric melanoma pilot-awards radiation oncology research awards Team Science translational research Uveal melanoma Young Investigator

King Albert II’s Brave Battle: A Decade of Fighting Skin Cancer

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification